Identification and characterization of C106R, a novel mutation in the DNA‐binding domain of GCMB, in a family with autosomal‐dominant hypoparathyroidism
- 8 November 2011
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 76 (5), 625-633
- https://doi.org/10.1111/j.1365-2265.2011.04256.x
Abstract
Overview Glial cells missing B (GCMB) is a transcription factor that is expressed in the parathyroid hormone (PTH)‐secreting cells of the parathyroid glands. Several mutations in GCMB have been reported to cause hypoparathyroidism (HP). We identified a family with two individuals in two generations (mother and son), who are affected by autosomal‐dominant hypoparathyroidism (AD‐HP). A novel heterozygous mutation in exon 2 of GCMB was identified in both affected individuals that changes cysteine at position 106 of the putative DNA‐binding domain of GCMB to arginine (C106R). Methods We performed mutational analysis of the genes encoding GCMB, pre‐pro PTH, GATA3 and CaSR using polymerase chain reaction (PCR)‐amplified genomic DNA. The identified GCMB mutant was characterized by functional studies including nuclear localization, electrophoretic mobility shift assays (EMSA) and luciferase reporter assays, and homology modelling was performed to generate a three‐dimensional structural model for the DNA‐binding domain of GCMB to predict the structural consequences of the identified mutation. Results The C106R mutant of GCMB failed to interact with the DNA consensus recognition motif, as determined by EMSA. Furthermore, in comparison with wild‐type GCMB, the C106R mutant demonstrated reduced transactivation in luciferase reporter assays; however, the mutant GCMB failed to reduce the activity of the wild‐type protein. Consistent with the EMSA findings, homology modelling analysis suggested that replacement of cysteine 106 with arginine would interfere with DNA binding. Conclusions We have identified a novel GCMB mutation that may explain AD‐HP in our family. However, the exact mechanism by which this heterozygous mutation leads to the disease in the described family remains to be elucidated.Keywords
This publication has 32 references indexed in Scilit:
- MafB interacts with Gcm2 and regulates parathyroid hormone expression and parathyroid developmentJournal of Bone and Mineral Research, 2011
- Identification and characterization of novel parathyroid-specific transcription factor Glial Cells Missing Homolog B (GCMB) mutations in eight families with autosomal recessive hypoparathyroidismHuman Molecular Genetics, 2010
- Presence and significance of a R110W mutation in the DNA-binding domain of GCM2 gene in patients with isolated hypoparathyroidism and their family membersActa Endocrinologica, 2010
- Glial Cells Missing-2 (GCM2) transactivates the calcium-sensing receptor gene: effect of a dominant-negative GCM2 mutant associated with autosomal dominant hypoparathyroidismHuman Mutation, 2009
- Dominant-NegativeGCMBMutations Cause an Autosomal Dominant Form of HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 2008
- Diagnosis and management of hypocalcaemiaBMJ, 2008
- The SWISS-MODEL workspace: a web-based environment for protein structure homology modellingBioinformatics, 2005
- Identification of a novel mutation disrupting the DNA binding activity of GCM2 in autosomal recessive familial isolated hypoparathyroidismJournal of Medical Genetics, 2005
- A novel activating mutation (C129S) in the calcium-sensing receptor gene in a Japanese family with autosomal dominant hypocalcemiaJournal of Human Genetics, 2001
- A Novel Mutation of the Signal Peptide of the Preproparathyroid Hormone Gene Associated with Autosomal Recessive Familial Isolated HypoparathyroidismJournal of Clinical Endocrinology & Metabolism, 1999